Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia: A pediatric case report

Pediatr Blood Cancer. 2023 Jul;70(7):e30308. doi: 10.1002/pbc.30308. Epub 2023 Mar 25.

Authors

Xiaojia Wen^{1

2

3

4}, Ying Wu^{1

2

3

4}, Pengli Huang^{1

2

3

4}, Huyong Zheng^{1

2

3

4}

Affiliations

¹ Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing, China.
² National Key Clinical Discipline of Pediatric Hematology, National Key Discipline of Pediatrics, Capital Medical University, Beijing, China.
³ Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China.
⁴ Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

PMID: 36965174
DOI: 10.1002/pbc.30308

No abstract available

Keywords: FLT3 inhibitors; FLT3-ITD; NUP98-NSD1; acute myeloid leukemia; dasatinib; venetoclax.

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Child
Dasatinib
Histone-Lysine N-Methyltransferase
Humans
Leukemia, Myeloid, Acute* / therapy
Mutation
Nuclear Pore Complex Proteins / genetics
fms-Like Tyrosine Kinase 3

Substances

Dasatinib
nuclear pore complex protein 98
venetoclax
Nuclear Pore Complex Proteins
fms-Like Tyrosine Kinase 3
FLT3 protein, human
Nup98 protein, human
NSD1 protein, human
Histone-Lysine N-Methyltransferase